{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-26-000002","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.402395+00:00","generated_at":"2026-05-16T11:21:13.194842+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AbbVie cuts Q4 2025 adjusted EPS guidance by $0.71 on $1.265B IPR&D charge","bullets":["Q4 2025 adjusted EPS guidance revised to $2.61-$2.65 from prior $3.32-$3.36.","Full-year 2025 adjusted EPS guidance lowered to $9.90-$9.94 from $10.61-$10.65.","Pre-tax acquired IPR&D and milestones expense of $1,265M (unfavorable $0.71 to GAAP and adjusted EPS).","Q4 2025 results not finalized; expense relates to collaborations and licensing deals.","AbbVie does not forecast IPR&D/milestones expense due to uncertainty."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-26-000002","json":"https://secwatch.observer/filing/0001551152-26-000002.json","markdown":"https://secwatch.observer/filing/0001551152-26-000002.md","text":"https://secwatch.observer/filing/0001551152-26-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000002/0001551152-26-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000002/abbv-20260107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:21:13.194842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}